Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
2024

Anti-PLA2R1 Antibodies and Kidney Transplant Recurrence

Sample size: 137 publication 10 minutes Evidence: high

Author Information

Author(s): Cremoni Marion, Teisseyre Maxime, Thaunat Olivier, Fernandez Céline, Payre Christine, Moutou Alan, Zarif Hadi, Brglez Vesna, Albano Laetitia, Moal Valérie, Mourad Georges, Morelon Emmanuel, Hurault de Ligny Bruno, Zaoui Philippe, Rondeau Eric, Ouali Nacera, Ronco Pierre, Moulin Bruno, Braun-Parvez Laura, Durrbach Antoine, Heng Anne-Elisabeth, Grimbert Philippe, Ducloux Didier, Blancho Gilles, Merville Pierre, Choukroun Gabriel, Le Meur Yannick, Vigneau Cécile, Mariat Christophe, Rostaing Lionel, Subra Jean-François, Taupin Jean-Luc, Lambeau Gérard, Esnault Vincent, Sicard Antoine, Seitz-Polski Barbara

Primary Institution: Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Centre Hospitier Universitaire de Nice, Nice, France

Hypothesis

The presence of pretransplant anti-PLA2R1 antibodies predicts the recurrence of membranous nephropathy after kidney transplantation.

Conclusion

Pretransplant anti-PLA2R1 antibodies are a strong predictor of membranous nephropathy recurrence after kidney transplantation.

Supporting Evidence

  • Patients with anti-PLA2R1 antibodies had a 54% recurrence rate compared to 9% in those without.
  • The study included 178 patients, with 137 analyzed after exclusions.
  • Monitoring anti-PLA2R1 antibodies post-transplant showed limited value for early recurrence.
  • Recurrence occurred rapidly, with a median delay of 5 months after transplantation.
  • Patients with recurrence had significantly higher pretransplant anti-PLA2R1 antibody levels.
  • Two cohorts were analyzed: one prospective and one retrospective.
  • Patients with high pretransplant antibody levels had a higher risk of allograft loss.
  • Statistical analyses confirmed the significance of the findings.

Takeaway

If patients have certain antibodies before getting a kidney transplant, they are more likely to have problems with their new kidney later on.

Methodology

A prospective multicenter study involving 72 patients and a retrospective cohort of 65 patients was conducted to evaluate the impact of anti-PLA2R1 antibodies on nephropathy recurrence.

Potential Biases

Potential bias due to the retrospective nature of part of the study and the exclusion of patients without pretransplant serum.

Limitations

The study did not have complete clinical data on allograft loss causes and lacked a consensus definition of recurrence.

Participant Demographics

The cohort included 137 patients, predominantly male (80%), with a mean age of 55 years.

Statistical Information

P-Value

<0.0001

Confidence Interval

95% CI: 2.3–15.7

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1016/j.ekir.2024.09.012

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication